• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » May 2009 – The CenterWatch Monthly : PDF
May 2009 – The CenterWatch Monthly : PDF

May 2009 – The CenterWatch Monthly : PDF

$79.00

Product Details

U.S. Sites Rate Novo Nordisk, Novartis and Eisai as Top Sponsors in 2009

Results of the CenterWatch 2009 Survey of Investigative Sites in the U.S. are in. For the second time in a row, U.S. sites have rated Novo Nordisk and Novartis the top one and two sponsors to work with, respectively. Eisai was ranked third by U.S. sites, a very high ranking considering that it is the first time that the company has elicited a significant response.

The total number of U.S. investigative sites responding to CenterWatch’s survey was 950, up nearly 50% the last time the survey was conducted two years ago. According to nearly half of responding sites, contract and budget negotiations are the factor that causes the most study delays.

CROs Going Private

Three large global CROs—Quintiles, PRA and PharmaNet—have gone private in recent years. Though each had company-specific reasons for the move, other large CROs may also want the freedom to pursue a long term strategic vision without worrying about the quarterly reporting demands of Wall Street.

Industry analysts believe that two or three small to mid-size public CROs that have weak financial results may consider going private in upcoming months, and a recent survey of public companies revealed that nearly one-quarter of respondents were considering going private due to corporate governance and disclosure reforms.

Inspection Programs Move from Retrospective to Risk-Based in Europe

Until the Clinical Trials Directive (2001/20/EC) went into effect five years ago, Good Clinical Practice (GCP) inspections were conducted retrospectively, often voluntarily and only with marketing authorization (MA) application. Now all 27 member states have at least one GCP inspector, and European Medicines Agency (EMEA) is using this collective body of expertise to widen the scope of inspections and push its prospective inspection program forward.

Eye On: Gastrointestinal Diseases

Gastrointestinal diseases may affect different sites in the entire digestive system from the mouth to the esophagus, stomach, small intestine, colon, rectum and anus. The liver, gallbladder and pancreas also secrete enzymes needed to break down and metabolize ingested food.

Symptoms of gastrointestinal disorders may include blood in the stool (melena or hematochezia), altered bowel habits, diarrhea or constipation, severe abdominal pain, unintentional weight loss and heartburn not responding to antacid treatment.

Also in this issue:

  • Month in Review
  • In the Pipeline
  • Opportunities Initiating
  • TrialWatch
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing